Actelion’s Tracleer Hangs On Against Label-Dampened Letairis

Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet